Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats

Psychopharmacology

Volumn 179, Issue 3, 2005, Pages 613-619

  Zhang, Han Ting ^a   Huang, Ying ^a   Suvarna, Neesha U ^a   Deng, Chengjun ^b   Crissman, Alicia M ^a   Hopper, Allen T ^b   De Vivo, Michael ^b   Rose, Gregory M ^b   O'Donnell, James M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Memory Pharmaceuticals Corporation   (United States)

Author keywords

Cyclic AMP; Inhibitory avoidance; Memory; NMDA; PDE4 inhibitor; Phosphodiesterase; Radial arm maze

Indexed keywords

CYCLIC AMP; DIZOCILPINE; MEM 1018; MEM 1091; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; RECOMBINANT ENZYME; ROLIPRAM; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN; BRAIN CORTEX; BRAIN NERVE CELL; CELL CULTURE; CELL LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; EXPERIMENTAL TEST; IN VITRO STUDY; INHIBITION KINETICS; MALE; MAZE TEST; MEMORY; NEWBORN; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; WORKING MEMORY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AVOIDANCE LEARNING; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MEMORY; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 18744416953     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2085-2     Document Type: Article

References (30)

1. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95:15020-15025
2. Barco A, Pittenger C, Kandel ER (2003) CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Exp Opin Ther Targets 7:101-114
3. Barnette MS, Underwood DC (2000) New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 6:164-169
4. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
5. Cherry JA, Davis RL (1999) Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and effect. J Comp Neurol 407:287-301
6. Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M (1997) Rolipram and its optimal isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 75:275-281
7. Fujimaki K, Morinobu S, Duman RS (2000) Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 22:42-51
8. Guzowski JF, McGaugh JL (1997) Antisense oligodeoxynucleotide-mediated disruption of hippocampal cAMP response element binding protein levels impairs consolidation of memory for water maze training. Proc Natl Acad Sci USA 94:2693-2698
9. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315
10. Houslay MD, Sullivan M, Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225-342
11. Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T, Ueki S (1997) Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 321:273-278
12. Liu R, Hess H-JE, Hopper A, Tehim A, Rong Y (2003) Phosphodiesterase 4 inhibitors. United States Patent Application Publication, Publication No. US 20030045533 A1
13. MacKenzie SJ, Houslay MD (2000) Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J 347:571-578
14. O'Donnell JM (2000) William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses. Exp Opin Invest Drugs 9:621-625
15. O'Donnell JM, Frith SA (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185-192
16. O'Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cyclic AMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158-163
17. Overstreet DH, Double K, Schiller GD (1989) Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain. Pharmacol Biochem Behav 34:691-696
18. 3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20:349-374
19. Schumacher RA, Brubaker WF, De Vivo M, Hess H-JE, Hopper A, Tehim A, Liu R, Unterbeck A (2004) Phosphodiesterase 4 inhibitors. United States Patent No. US 6,669,890
20. Silvestre JS, Fernandez AG, Palacios JM (1999a) Effects of rolipram on the elevated plus-maze test in rats: a preliminary study. J Psychopharmacol 13:274-277
21. Silvestre JS, Fernandez AG, Palacios JM (1999b) Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats. Pharmacol Biochem Behav 64: 1-5
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
23. Suvarna NU, O'Donnell JM (2002) Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 302: 249-256
24. Taylor JR, Birnbaum S, Ubriani R, Arnsten AF (1999) Activation of cAMP-dependent protein kinase A in prefrontal cortex impairs working memory performance. J Neurosci 19(RC23):1-5
25. Wang D, Deng C, Bugaj-Gaweda B, Kwan M, Gunwaldsen C, Leonard C, Xin X, Hu Y, Unterbeck A, De Vivo M (2003) Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7. Cell Signal 15:883-891
26. Zhang HT, O'Donnell JM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial arm maze tests in rats. Psychopharmacology 150:311-316
27. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198-204
28. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587-595
29. Zhang HT, Huang Y, Jin SLC, Frith S, Zhao Y, Suvarna N, Conti M, Steketee JD, O'Donnell JM (2003) Cyclic AMP-specific phosphodiesterase 4 (PDE4): memory, emotion, and drug abuse. Society for Neuroscience, 33nd Annual meeting, New Orleans, USA
30. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O'Donnell JM (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432-1439